Boston Scientific (BSX) lost nearly 6% in the premarket on Wednesday despite reporting better-than-expected Q2 2026 financials as the medical device maker set its Q3 and full-year earnings outlook below analystsâ estimates. The Massachusetts-based MedTech reported $5.4B in
Boston Scientific (BSX) lost nearly 6% in the premarket on Wednesday despite reporting better-than-expected Q2 2026 financials as the medical device maker set its Q3 and full-year earnings outlook below analystsâ estimates.
The Massachusetts-based MedTech reported $5.4B in revenue for the
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
